[Comparison of clinical characteristics and laboratory parameters of patients with dermatomyositis-specific autoantibodies and autoantibody-negative patients].

Item request has been placed! ×
Item request cannot be made. ×
loading   Processing Request
Read More Add to Saved list
  • Additional Information
    • Transliterated Title:
      Dermatomyositis-specifikus autoantitesttel rendelkező és autoantitest-negatív betegeink klinikai jellemzőinek és laboratóriumi paramétereinek összehasonlítása.
    • Source:
      Publisher: Akademiai Kiado Country of Publication: Hungary NLM ID: 0376412 Publication Model: Print Cited Medium: Print ISSN: 0030-6002 (Print) Linking ISSN: 00306002 NLM ISO Abbreviation: Orv Hetil Subsets: MEDLINE
    • Publication Information:
      Publication: 2007- : Budapest : Akademiai Kiado
      Original Publication: Pest : Markusovszky Lajos
    • Subject Terms:
      Autoantibodies/*blood ; Dermatomyositis/*immunology ; Muscle Weakness/*immunology; Adult ; Dermatomyositis/complications ; Dermatomyositis/physiopathology ; Female ; Humans ; Immunoblotting ; Immunoprecipitation ; Male ; Middle Aged ; Retrospective Studies ; Treatment Outcome
    • Abstract:
      Introduction: Myositis is an autoimmune disease characterised by proximal muscle weakness.
      Aim: The aim of the authors was to determine the frequency of dermatomyositis-specific autoantibodies (anti-Mi-2, anti-transcriptional intermediary factor 1 gamma, anti-nuclear matrix protein 2, anti-small ubiquitin-like modifier activating enzyme, anti-melanoma differentiation-associated gene) in a Hungarian myositis population and to compare the clinical features with the characteristics of patients without myositis-specific antibodies.
      Method: Antibodies were detected using immunoblot and immunoprecipitation.
      Results: Of the 330 patients with myositis, 48 patients showed dermatomyositis-specific antibody positivity. The frequency of antibodies in these patients was lower than those published in literature Retrospective analysis of clinical findings and medical history revealed that patients with dermatomyositis-specific autoantibody had more severe muscle weakness and severe skin lesions at the beginning of the disease.
      Conclusions: Antibodies seem to be useful markers for distinct clinical subsets, for predicting the prognosis of myositis and the effectiveness of the therapy.
    • Contributed Indexing:
      Keywords: anti-Mi-2; anti-NXP2; anti-TIF1-γ; anti-TIF1γ; myositis; myositis-specific autoantibody; myositisspecifikus autoantitest
    • Accession Number:
      0 (Autoantibodies)
      0 (Mi-2 antibodies)
    • Publication Date:
      Date Created: 20150901 Date Completed: 20151216 Latest Revision: 20150831
    • Publication Date:
      20221213
    • Accession Number:
      10.1556/650.2015.30221
    • Accession Number:
      26320599